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TAL Effector Nucleases (TALENs) are versatile tools for targeted gene editing in various species. However,
their efficiency is still insufficient, especially in mammalian embryos. Here, we showed that combined
expression of Exonuclease 1 (Exo1) with engineered site-specific TALENs provided highly efficient
disruption of the endogenous gene in rat fibroblast cells. A similar increased efficiency of up to,30% with
Exo1 was also observed in fertilized rat eggs, and in the production of knockout rats for the albino (Tyr)
gene. These findings demonstrate TALENs with Exo1 is an easy and efficient method of generating gene
knockouts using zygotes, which increases the range of gene targeting technologies available to various
species.
G
enetically engineered animals provide a powerful tool for the functional annotation of genes and for
modeling human genetic diseases. Advances over the past 20 years in mouse embryonic stem cells and
homologous recombination (HR)-mediated targeting have made this species the first choice for model-
ing human diseases. However, these technologies were only available in mice, and not in other species. Recently,
new technologies have been developed and tested for gene disruption, and HR could prove an invaluable tool for
the rapid generation of genetically modified animals. These new approaches include zinc-finger nucleases
(ZFNs), comprising the DNA-binding domain of zinc-finger proteins fused with the non-specific DNA endo-
nuclease FokI1–4, and transcription activator-like effector nucleases (TALENs), comprising an engineered array of
TAL effector repeats fused to the FokI nuclease domain5–8. These engineered nucleases can recognize long
stretches of DNA sequences and introduce DNA double-strand breaks (DSBs). DSBs are mainly restored via
non-homologous end-joining (NHEJ), a process that introduces small insertions or deletions (indels) at the repair
junction, thereby generating mutations at the targeted sequences1–8. They are especially useful in previously non-
permissive model organisms, such as sea urchins9, crickets10, medaka fish11, or rats12–14.
ZFNs/TALENs provide a straightforward strategy for targeted gene disruption in zygotes, resulting in rapid
and cost-effective knockouts. Although both commercial and open resources are available for the design of ZFN/
TALEN reagents, ZFNs present hurdles in terms of cost and protocols, making it difficult to establish ZFNs as a
routine laboratory process. The sequences recognized by ZF domains are also limited, whereas TAL effectors can
recognize almost any sequence, except T at position 05,7,8. Simple and straightforward design and assembly
strategies have been developed for rapid construction of TALENs, providing a cost-effective targeted nuclease
platform. Although TALEN technologies have advantages, the technology remains uncertain because its intro-
duction is so recent6. Since the original discovery of TAL effectors in the plant pathogenic bacteria,Xanthomonas,
the system appears to be less effective in rodent embryos, such as mice and rats (unpublished data, personal
communication). The larger size of the proteins may also impede the gene targeting efficiency compared with
ZFNs, even though the recently reported truncation of the N- and C-terminal regions of the native proteins has
increased the TALEN DSB-activity15. Improved methodology is needed to further exploit the utility of this
technology. For example, a recent report showed that coupling designer endonucleases withDNA end-processing
enzymes could improve gene disruption rates in mouse and human cells16. To address this issue, we co-expressed
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Results
Construction of TAL effecter nucleases and the single-strand
annealing (SSA) assay. Over 100 strains of albino rats deposited
into the National Bio Resource Project – Rat (http://www.anim.med.
kyoto-u.ac.jp/nbr/) have the samemissensemutation (Arg299His) in
the Tyrosinase (Tyr) gene17. The coat-color phenotype is easily and
observably distinguishable for TALEN-induced mutations; there-
fore, we targeted the rat Tyr gene. A pair of TALENs was con-
structed using a two-step assembly method18 with a Golden Gate
TALEN kit, originally established from the Voytas lab19 (Figure 1A).
For the subsequent use of TALENs in the SSA assay, transfection into
cultured cells, and mRNA synthesis, the backbone vectors for the
second-step assembly were replaced with the mammalian expression
vector pcDNA-TAL vector, which has CMV and T7 promoters18. The
TALEN-based constructs were also replaced with deletion frameworks
of 1153 N- and 147 C-terminal domains, termed the NC scaffold, as
previously reported15 (Figure 1B).
We then performed a validation test of the mammalian cell-
based SSA assay in human embryonic kidney 293T (HEK293T)
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Figure 1 | TALEN constructs and the validation of their activity in rat fibroblasts. (A) Structure of engineered TALENs binding to exon 2 of rat
Tyrosinase (Tyr) gene. (B) TALEN scaffolds (upper) and N- and C-terminal truncated scaffolds (lower), respectively. (C) Relative TALEN activity
measured by a single-strand annealing (SSA) assay in human embryonic kidney 293T (HEK293T) cells. (D) Surveyor (Cel-I) nuclease assay for TALEN-
induced mutations in Tyr. Arrowheads indicate the expected positions of the digested products. (E) Surveyor assay showing that increased frequency of
TALEN-induced mutations by NC truncation and co-expression of Exo1. Data are expressed as means 6 SEM (n 5 3). *P,0.01 by Student’s t-tests.
(F–H) Sequence analyses showing increased mutation efficiency by NC truncation and Exo1 expression. Microhomologous sequences adjacent to the
breakpoint are underlined for TALEN (F), TALEN-NC (G), and TALEN-NC 1 Exo1 (H).
www.nature.com/scientificreports
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Compared with the positive control (ZFN transfected cells9) and
negative controls (reporter vectors with unrelated sequences), the
cells transfected with Tyr-TALENs showed marked activation of
the luciferase gene at about 60% of the value of the ZFN positive
control. The cells transfected with Tyr-TALENs-NC showed 40%
higher activity than the ZFN treated cells, indicating that the cus-
tom-engineered TALENs have the cleavage activity and that the NC
truncation of TALENs increases the cleavage efficiency in the SSA
assay (Figure 1C).
Combination of exonucleases with TALENs increased the effici-
ency of targeted gene disruption in rat fibroblasts. To assess the
activity of the TALEN architectures against an endogenous gene, we
electroporated Tyr-TALEN or Tyr-TALEN-NC expression vectors,
and the GFP expression vector as a negative control, into Rat-1
fibroblast cells (Table 1). After 24 h, the control cells showed more
than 90% GFP-positive cells, indicating sufficient transformation
rates. After 72 h, cell numbers were counted, and genomic DNA
was extracted and screened for TALEN-induced mutations using
the Surveyor (Cel-I) nuclease assay (Figure 1D). Similar to the
results of the SSA assay, TALENs-NC showed higher activity than
TALENs (11.0% vs. 6.1%) in Rat-1 cells (Figure 1E). However,
compared with our previous results using ZFNs (mutation rates
,25%13,20), the TALEN activity was significantly lower.
To increase the frequency of TALEN-induced mutations, we
added vectors expressing the Exo1 gene. Co-transfection of the
Exo1 vectors and TALEN-NC showed significantly higher activity
(25.9%) compared with TALEN-NC alone in the Surveyor assay
(Figure 1D, E). Sequence analyses of the Tyr loci revealed similar
mutation rates to the results of the Surveyor assay: 5.7%, 7.3%, and
17.7% in TALEN, TALEN-NC, and TALEN-NC 1 Exo1 transfected
cells, respectively (Table 1). There was no difference in the types of
indel mutation or their sizes, which ranged from a 1-bp insertion to
a 53-bp deletion centered over the TALEN recognition sites
(Figure 1F–H).
Exo1 increases the frequency of TALEN-induced gene disruption
in rat zygotes. To evaluate the gene targeting efficiency of TALENs
in zygotes, we microinjected mRNA of the assembled Tyr-TALEN-
NC with and without in vitro transcribed Exo1mRNA into fertilized
rat eggs (Figure 2A, B). After 24 h, 30–40% of the TALENs-injected
embryos differentiated normally into two-cell embryos with or
without Exo1. PCR and sequence analyses on the two-cell embryos
detected amutation rate of 5.6% (1/18) in TALEN-NC and 28.6% (4/
14) in TALEN-NC with Exo1, indicating that Exo1 increases the
frequency of TALEN-induced mutations in zygotes (Figure 2A).
Interestingly, PCR and sequence analyses revealed that TALEN-in-
jection into fertilized eggs could introduce homozygous mutations,
which could not be detected by the Surveyor assay (Figure 2C, D).
This means TALEN-induced mutations created by NHEJ could be
induced at the one-cell stage, presumably during the S-phase (the
DNA synthesis phase) of the cell cycle, in fertilized eggs.
Coinjection of TALENs mRNA with Exo1 mRNA into embryos
provides efficient generation of knockout rats. To generate knock-
out rats for the albino locus by TALENs, we again microinjected
mRNA for TALENs or TALENs-NC into fertilized eggs of agouti
DA rats. Of 328 TALEN-injected eggs, 126 two-cell embryos (38.4%)
were transferred into the oviducts of pseudopregnant Wistar female
rats, and 29 (23.0%) of these embryos were successfully carried to
term (Figure 3A). However, nomutant pupwas detected by sequence
analyses of the targeted Tyr locus. Microinjection of TALENs com-
mercially obtained from Cellectis (Paris, France) delivered two mu-
tant pups among 30 born (6.7%) (Figure 3A). When we coinjected
Exo1mRNA with TALENs-NC, 29 two-cell embryos were obtained
from 68 injected eggs (42.6%) without obvious toxicity, and of 12
pups delivered (41.4%), three founders possessed mutations
comprising 5- to 29-bp deletions (25.0%) (Figure 3B, C).
One male founder showed the albino coat-color phenotype over
its entire body (Figure 3B), and sequence analyses revealed that this
founder carried a homozygousmutation (a 29-bp deletion) at theTyr
locus (Figure 3C). When we crossed the founders with the DA
strains, the TALEN-induced mutations were faithfully transmitted
to the next generation. For example, a male G0 founder showing a
mosaic coat-color phenotype was crossed with a DA female to obtain
G1 heterozygotes. Subsequent intercrossing between G1 heterozyg-
ous males and females produced homozygous albino G2 offspring
(Supplementary Fig. S1).
Discussion
As far as we know, this is the first report to show that coinjection of
exonuclease Exo1with engineered nucleases, such as TALENs, could
enhance the frequency of targeted gene disruption in zygotes, and
could improve the targeting efficiency to generate knockout animals.
This approach provides an easy, rapid and efficient method of gen-
erating knockout animals (Supplementary Fig. S2). For example, the
custom design and assembly of TALENs and their validation by the
SSA assay took 1–2 weeks. Direct injection of the engineered
TALENs with pre-transcribed Exo1 into embryos, transplantation
into pseudopregnant foster mothers, and identification of TALEN-
induced mutants took 1 month. A homozygous mutation producing
an albino G0 founder was observed 3 weeks after birth. It will be
interesting to determine how TALENs targeted both alleles to pro-
duce the homozygous mutation in zygotes, as has been observed in
our previous experiments with ZFNs13. In addition, in our in vitro
and in embryo experiments, no overt toxicity was observed when
overexpressing Exo1 in conjunction with TALENs.We also observed
no effect of Exo1 on the cell cycle and cell growth, or on embryo
survival and embryo development. Although Exo1 could increase the
number of mutations at off-target sites, TALENs seem to have fewer
off-target effects than ZFNs21. Although off-target effects might play
a role in cell-based experiments, in animals such unknownmutations
will be ‘‘washed out’’ by repetitive subsequent backcrossing with the
parental strain.
It remains unclear how exonucleases enhance the efficiency of
TALEN-induced gene disruption in zygotes. Exo1 is a 59–39 exonu-
clease that has a major role in DSB-repair by 59-strand resection of
DSB-ends22–26. There are two major pathways for DSB-repair: NHEJ
and HR. Recently, a third pathway, alternative NHEJ (altNHEJ), or
microhomology mediated end-joining (MMEJ), was shown to repair
DSBs in the absence or failure of the classical NHEJ (cNHEJ)
Table 1 | Surveyor assay and sequencing for TALEN-induced mutations in Rat-1 fibroblasts
Plasmid(s) Cell No. (1 3 105) Surveyor assay (%)
Sequence analysis
Mutations/Colonies Mutation Rate (%) Average del size (bp)
GFP 2.44 6 0.58 0.44 6 0.71 — — —
TALEN 2.81 6 0.23 6.06 6 0.56 5/96 5.2 14.2 6 6.5
TALEN-NC 2.72 6 0.33 11.04 6 1.77 7/96 7.3 17.4 6 6.8
TALEN-NC 1 Exo1 3.02 6 0.35 25.86 6 1.91 17/96 17.7 11.9 6 2.6
www.nature.com/scientificreports
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pathway27–29 (Figure 4). DSBs created by ZFNs or TALENs are gen-
erally repaired by cNHEJ with precise DNA-ends joining. When
precise repair fails, or after the recession of DNA-ends by DNA
exonucleases, DSBs would be repaired by altNHEJ, typically using
closermicrohomology sequences at both ends, thereby drivingmuta-
genic end processing. Overexpression of Exo1 probably increases
DNA-end resections at the DSB-ends created by TALENs, thereby
increasing the frequency of mutagenic DSB-repair via altNHEJ. To
examine the effects of overexpression of Exo1 on the NHEJ and HR
pathways, we performed anNHEJ assay thatmeasures the repair of I-
SceI-generated DSBs via the NHEJ pathway20,30 and an HR assay that
measures the repair of I-SceI-generated DSBs via the HR pathway20,31
(Supplementary Fig. S3). Those assays revealed that the Exo1 signifi-
cantly inhibited both the NHEJ pathway and the HR pathway in a
wide variety of human cells (U2OS, HeLa, and MRC5), suggesting
that the altNHEJ pathway would be enhanced in compensation,
which might increase the frequency of the targeted gene disruption.
In conclusion, coinjection of exonucleases Exo1 with TALENs
provides an easy and efficient approach for gene knockouts in
zygotes, and represents a promising breakthrough for gene targeting
technologies applicable to various species.
Methods
Animals. All animal care and experiments conformed to the Guidelines for Animal
Experiments of Kyoto University, and were approved by the Animal Research
Committee of Kyoto University. Novel developed DA-Tyrem1Kyo albino rats (NBRP-
Rat No.0666) were deposited into the National Bio Resource Project – Rat in Japan
(www.anim.med.kyoto-u.ac.jp/nbr).
Construction of TALEN plasmids and single-strand annealing (SSA) assay. The
protocol for TALEN assembly was as previously reported18,19. Repeat assembly was
conducted using a Golden Gate reaction, transformed into XL1-Blue competent cells
and screened for precisely assembled clones by colony PCR using the pCR8_F1
and pCR8_R1 primers19. Constructed array plasmids and the appropriate last repeat
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Figure 2 | Targeted gene disruption by engineered TALENs in rat embryos. (A) Injection of TALEN-NC with or without Exo1mRNA into rat fertilized
eggs. Exo1 increased the efficiency of TALEN-induced mutations in zygotes by ,53. (B) Microinjection of TALENs mRNA into male pronuclei of a
fertilized egg. (C) Surveyor assay on the PCR products shows a TALEN-induced mutation as the digested products (arrowheads) in lane 6, but could not
detect a homozygous mutation in lane 2. (D) Sequence analyses of the PCR products showed a 24-bp deletion in the homozygous alleles (eT-NC-Exo1-
#2). Microhomologous sequences adjacent to the breakpoint are underlined.
www.nature.com/scientificreports
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pcDNA-TAL-NC18. Final assembly, transformation and colony PCR screening for
the second Golden Gate reaction were performed as previously reported18,19.
The SSA assay was carried out as previously described9. The pGL4-SSA reporter
vector was generated, containing inactive fragments of the luciferase gene, which bear
700-bp regions of homologous overlap and are driven by a cytomegalovirus (CMV)
immediate-early enhancer/promoter. For the addition of TALEN target sequences,
sense and antisense oligonucleotides, Sense: 5’- GTCGGATATAATAGCCATC-
AGGTTTTATGTGATGGAACACCTGAGGGACCACTATTACGTAATCCTGG-
AGGT-3’, and Antisense: 5’- CGGTACCTCCAGGATTACGTAATAGTGGTCC-
CTCAGGTGTTCCATCACATAAAACCTGATGGCTATTATATC-3’, were
annealed and inserted into BsaI sites between the dissected luciferase elements of
pGL4-SSA. For the ZFN positive control, a ZFN expression vector, pSTL-ZFA36, was
constructed, as previously described9.
RatExo1 cDNA cloning.To clone the ratExo1 cDNA, first strand cDNAwas isolated
using the oligo(dT)12-18 primer and SuperscriptII reverse transcriptase (Life
Technologies, Carlsbad, CA, USA) synthesized from total RNA extracted from the
brain of F344 rats by the Isogen reagent (Nippon Gene, Tokyo, Japan). RT-PCR was
performed with the primers: 5’-GGGCCATGCCTGTTTATTC-3’ and 5’-
TGTTACCAGTGTGTTACCAGTCG-3’. RT-PCR products were inserted into
pGEM-T Easy (Promega, Fitchburg, USA) and sequenced to confirm the sequence.
For expression in vitro, the full-length cDNAwas subcloned into pcDNA6.2/V5/GW/
D-TOPO (Life Technologies).
Cell culture and transfection.Rat fibroblast-like (Rat-1) cells were obtained from the
RIKEN BRC Cell Bank (Tsukuba, Japan, http://www.brc.riken.jp/lab/cell/english).
The Rat-1 cells were cultured in DMEM (Invitrogen), supplemented with 10% FBS
(fetal bovine serum, CBB) in a humidified atmosphere containing 5% CO2 at 37uC.
The cells (1 3 105) were suspended in 10 ml R buffer (supplied as part of the Neon
Transfection System, Invitrogen), given 0.5 mg of each plasmid, and electroporated
under the following conditions: pulse voltage, 1300 V; pulse width, 20 ms; and pulse
In jected  m R N A In jected  em bryos
Tw o-ce ll
em bryos (% ) P ups (% ) 䄟 䄝 M utants (% )
TA LE N 127 40 (31 .5 ) 9 (23 .0 ) 5 4 0 (0)
TA LE N -N C 201 86 (42 .8 ) 20 (23 .3 ) 10 10 0 (0)
TA LE N (C e llectis ) 290 92 (31 .7 ) 30 (32 .6 ) 14 16 2 (6 .7 )













gT-N C -E xo1-#2
Figure 3 | Efficient generation of knockout rats using TALENs with Exo1. (A) Microinjection of TALENs, TALENs-NC, TALENs from Cellectis, and
TALENs-NCwith Exo1 into fertilized eggs of agouti DA rats. Coinjection of TALEN-NCmRNAwith Exo1mRNA provided higher mutational efficiency
(25%) in pups. (B) Thewhite coat-color of an albinomale rat (right) obtained by coinjection of TALEN-NC and Exo1. An agoutimale (left) is a littermate.





















Figure 4 | Schematics of exonucleases (Exo1) functions in double-
stranded break (DSB) repair pathways. Alternative NHEJ (altNHEJ), or
microhomology mediated end-joining (MMEJ), generally repairs DSBs in
the absence or failure of the classical NHEJ (cNHEJ) pathway27–29.
Overexpression of Exo1 induces increased recessions of DNA-ends at the
DSB created by TALENs, which inhibits cNHEJ (See Supplementary Fig.
S3) and enhances themutagenic DSB-repair via altNHEJ, resulting inmore
indel mutations at the targeted gene.
www.nature.com/scientificreports
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number, 2 (program #15). Following electroporation, the cells were cultured in the
medium described above without antibiotics for 24 h and then in the medium with
antibiotics for 48 h. The in vitro transfer experiment was replicated three times.
Surveyor assay and DNA sequencing. For the Surveyor assay to detect TALEN-
induced mutations, the SURVEYOR Mutation Detection Kit (Transgenomic,
Omaha, NE, USA) was used in accordance with the manufacturer’s protocol. Briefly,
72 h after electroporation, genomic DNA was extracted from the Rat-1 cells using
Nucleospin (Macherey-Nagel, Du¨ren, Germany). PCR was then performed using
PrimeSTAR HS DNA polymerase (Takara Bio, Shiga, Japan), a high-fidelity enzyme,
under the following conditions: 95uC for 1 min; followed by 95uC for 30 s, 68uC for
30 s, and 72uC for 1 min for 35 cycles. The PCR primers were as follows: 59-
TTGCATAAATTGGTTTTCACAGA-39 and 59-ATTTAAACATGAAAATAT-
TACCTTCCA-39. The PCR amplification products were heat denatured, digested by
the Surveyor nuclease, and subjected to agarose gel electrophoresis to confirm
TALEN-induced mutations.
For DNA sequencing analysis, the PCR products were subcloned into pCR4Blunt-
TOPO plasmid vector (Life Technologies). Plasmids were extracted from the res-
ultant Escherichia coli colonies for DNA sequencing. Sequencing was performed
using the BigDye Terminator Cycle Sequencing Kit and an ABI PRISM 3130 Genetic
Analyzer (Life Technologies).
Rat embryo culture.Pronuclear stage embryos were collected fromDA/Slc females at
7 weeks of age that had undergone super-ovulation by injection with PMSG
(Serotropin, Aska Pharmaceutical Co., Tokyo, Japan) and hCG (Gonatropin, Aska
Pharmaceutical Co.). The GenomPlex Single Cell Whole Genome Amplification Kit
(WGA4; Sigma Aldrich, St. Louis, MO, USA) was used to generate proprietary
amplification of genomic DNA with universal oligonucleotide primers from a two-
cell embryo. After purification, the single cell WGA products were analyzed the
Surveyor assay and DNA sequencing analysis.
Microinjection of TALENs mRNA. To prepare mRNA of TALENs, TALEN-
encoding expression plasmids were linearized with XhoI and extracted with phenol-
chloroform by standard methods. To prepare the mRNA for Exo1, the Exo1 plasmids
were linearized with SpeI. Messenger RNA was transcribed in vitro using a
MessageMaxTM T7 mRNA transcription kit (Illumina, San Diego, CA, USA) and
polyadenylated using a A-PlusTM Poly(A) polymerase tailing kit (Illumina). The
resultant mRNA was purified using a MEGAClearTM kit (Illumina) and finally
resuspended in RNase-free water at 10 ng/ml for each TALEN or Exo1.
Approximately 2-3 pL of capped mRNA were injected into the male pronuclei of
zygotes by microinjection13. The injected embryos were cultured in mKRB at 37uC
with 5% CO2 and 95% humidified air to promote their recovery. Surviving embryos
were transferred to the oviducts of pseudopregnant Wistar females.
NHEJ and HR assays. NHEJ and HR assays were performed as previously
reported20,30,31. MRC5SV-pEJ cells were used for the NHEJ assay. U2OS-DRGFP,
HeLa-DRGFP and MRC5SV-DRGFP were used for the HR assay. To measure the
repair of I-SceI-generated DSBs, 50 mg of the I-SceI expression vector (pCBASce)
with or without a human Exo1 expression plasmid (30 mg) was introduced into 5 3
106 cells by electroporation (GenePulser; Bio-Rad, Hercules, CA,USA). To determine
the level of NHEJ or HR repair, the percentage of GFP-positive cells was quantified by
flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA) 3 days
after electroporation.
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